Navigation Links
Neurochem reports results for third quarter of fiscal 2007
Date:11/7/2007

cognized is in respect of the non-refundable upfront payment received from Centocor, which is being amortized over the estimated period through to the anticipated regulatory approval date of the investigational product candidate. The estimated period is subject to change based on additional information that the Company may receive periodically. The other portion of the upfront payment received from Centocor ($6,000,000) has been classified as deferred revenue and is not being amortized as earned revenue given that it is potentially refundable. In the event that the Company receives an approval letter issued by the US Food and Drug Administration (FDA), the amount would no longer be refundable and would be amortized as earned revenue. In July 2007, the Company received a second approvable letter from the FDA for eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis. In this action letter, the FDA indicated that an additional efficacy trial will be necessary before the FDA could approve the investigational product candidate. The approvable letter also states that additional submissions, filed by Neurochem as part of its response to this approvable letter, may address issues raised in this letter. The FDA has indicated that additional submissions could persuade the agency to eliminate the requirement for an additional trial. The FDA also asked for additional information, including further pharmacokinetic studies, and again acknowledged that a QT clinical study should be submitted as part of a Phase IV (post-approval) commitment. The Company filed a response to this second approvable letter in late September 2007. Neurochem has also submitted for marketing approval for eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis in the European Union and Switzerland. In September 2006, the European Medicines Agency (EMEA) confirmed that it had commenced a regulatory review of eprodisate (KIACTA(TM)). An oral hearing is scheduled with the EMEA in November 2007 to di
'/>"/>
SOURCE NEUROCHEM INC.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014 Eufaula, Oklahoma, located just ... Eufaula, the state’s largest lake with more than 600 ... home to a little more than 3,000 residents, hosted ... Saturday, the 6th of December. , Featuring Santa, Christmas ... downtown Eufaula on Main Street. Narconon Arrowhead’s parade ...
(Date:12/19/2014)... The print component of Vision and ... of the Toronto Star, with a circulation of approximately ... digital component is distributed nationally through a vast social ... sites and partner outlets. To explore the digital version ... publication features an exclusive interview with Mark DeMontis ...
(Date:12/19/2014)... 19, 2014 (HealthDay News) -- Potentially illness-causing E. coli ... at farmers markets, according to a new study. ... vendors from 13 farmers markets in Los Angeles and ... Out of almost 150 samples tested, 24 percent were ... salmonella, according to the researchers. Both types of ...
(Date:12/19/2014)... who have lost all their teeth have faster decreases in ... least some of their teeth, a new study says. ... early warning of increased risk of physical and mental decline ... findings don,t prove that tooth loss causes the physical or ... 60 and older. People with no remaining teeth did about ...
(Date:12/19/2014)... Kan. (PRWEB) December 19, 2014 B. ... exclusively to healthcare providers, has been retained to lead ... Estes Park Medical Center in Estes Park, Colo. The ... E. Smith has recently placed more than 900 healthcare ... (EPMC) is a 25-bed, not-for-profit critical access hospital and ...
Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2Health News:E. Coli Germs Found on Farmers Market Herbs 2Health News:Loss of Teeth Linked to Physical, Mental Decline in Study 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3
... American Society,of Consultant Pharmacists (ASCP) announces that Outcomes ... Medication Therapy,Management (MTM) Provider Partners. This announcement was ... 38th Annual Meeting and Exhibition,taking place in Philadelphia., ... MTM services has increased,dramatically since the coverage of ...
... years that psychological trauma that results in post-traumatic ... a person responds to stress. Now, Cornell researchers ... life-threatening accidents and other such traumas may result ... develop a clinical disorder., "The findings suggest that ...
... JAPAN, November 20, 2007 Bristol-Myers Squibb Company (NYSE: ... the U.S. Food and Drug Administration (FDA) approved the ... add-on, treatment to antidepressant therapy (ADT) in adults with ... medication approved by the FDA as add-on treatment for ...
... 20 Crdentia Corp. (OTC Bulletin,Board: CRDT), a ... Ms. Penny Kirsch to Vice President of Human ... Manager,for Crdentia and will continue to report to ... be responsible for all human resources operations for ...
... Nov. 20 SyntheMed, Inc. (OTC,Bulletin Board: SYMD), a ... and drug delivery products, today,announced that President and CEO ... Markets Fourth Annual Healthcare Conference at the Palace,Hotel in ... 1:30 p.m. EST. Lazard Capital Markets will host ...
... Molecular Imaging Zone, FORT LAUDERDALE, Fla., Nov. ... IMDS) a pioneer in laser,optical breast cancer imaging ... cases imaged with optical computed tomography,technologies at RSNA ... 28. A CT,Laser Mammography (CTLM(R)) system and clinical ...
Cached Medicine News:Health News:Outcomes Pharmaceutical Health Care(r) Becomes an ASCP MTM Provider Partner 2Health News:FDA approves ABILIFY(R) (aripiprazole) as the first medication for add-on treatment of MDD 2Health News:FDA approves ABILIFY(R) (aripiprazole) as the first medication for add-on treatment of MDD 3Health News:FDA approves ABILIFY(R) (aripiprazole) as the first medication for add-on treatment of MDD 4Health News:FDA approves ABILIFY(R) (aripiprazole) as the first medication for add-on treatment of MDD 5Health News:Crdentia Announces Promotion of Penny Kirsch to Vice President of Human Resources 2Health News:Crdentia Announces Promotion of Penny Kirsch to Vice President of Human Resources 3Health News:Imaging Diagnostic Systems to Present Laser Breast Imaging Clinical Results at the 2007 Radiological Society of North America Scientific Assembly 2Health News:Imaging Diagnostic Systems to Present Laser Breast Imaging Clinical Results at the 2007 Radiological Society of North America Scientific Assembly 3
(Date:12/17/2014)... -- Strategic Health Services, Inc. (SHS), a leading provider of ... agreement with QualCare, Inc., a leading provider of health plans ... marketplace.  This agreement will further QualCare,s population health management ... brings to its clients in New Jersey ... QualCare plans cover more than 800,000 member lives, with ...
(Date:12/17/2014)... December 17, 2014 , ... than a hub of information concerning the biopharmaceutical Group,s national ... A further addition to the recently launched institutional website that ... now been enriched by a new chapter in the fascinating ... A richly detailed and panoramic hub on the world of ...
(Date:12/17/2014)... Ga. and RALEIGH, N.C. ... Trial Marketing Communications, LLC (CTMC), and Integrated Clinical ... patient recruitment and retention for clinical trials announce ... Integrated Clinical Trial Marketing Services (i-CTMS). i-CTMS will ... retention services to pharmaceutical, biotechnology and medical device ...
Breaking Medicine Technology:Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3
... France and SWIFTWATER, Pa., June 16 Sanofi,Pasteur, the ... donate 60 million doses of H5N1 vaccine to the ... of an H5N1 vaccine,global stockpile., "The H5N1 virus ... the world and an outbreak of pandemic influenza would ...
... Results presented at the 90th annual Endocrine Society meeting show,significant ... ... painful intercourse, ANN ARBOR, Mich, June 16 QuatRx ... 3 clinical,trial of Ophena(TM) (ospemifene tablets) to treat postmenopausal women ...
Cached Medicine Technology:Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile 2Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile 3Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile 4Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile 5Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy 2Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy 3Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy 4
The Fujinon's R410 laparoscope is the first to bring a 410,000 pixel CCD to the end of the scope. Superior imaging and color replication, along with a unique lens washing capability make the R410 the...
The ACMI™ Operative Laparoscopy System is designed for single- and dual-incision CO2 laser procedures and is used with 45cm laparoscopic instruments....
The edge-to-edge clarity of the laparoscopes provides excellent image definition.Even small structures are easily recognized due to the optimal depth of focus. The outstanding optical quality provide...
Stryker bariatric laparoscopes set the standard in picture quality....
Medicine Products: